<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6770">
  <stage>Registered</stage>
  <submitdate>2/06/2005</submitdate>
  <approvaldate>2/06/2005</approvaldate>
  <nctid>NCT00112931</nctid>
  <trial_identification>
    <studytitle>Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma</studytitle>
    <scientifictitle>An Intergroup Randomised Trial of Rituximab Versus a Watch and Wait Strategy in Patients With Advanced Stage, Asymptomatic, Non-Bulky Follicular Lymphoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CRUK-2004-001621-16</secondaryid>
    <secondaryid>CDR0000427312</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Lymphoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - rituximab
Other interventions - No treatment

Active Comparator: Watch and Wait - Watch and Wait - no treatment

Experimental: Arm C Rituximab 4 and Rixuximab Maintenance - 4 infusions - 375mg/m2 every 2 months. A single dose of rituximab (375mg/m2 will then be given at 12, 20, 28, 36, 44, 52, 60, 68, 76, 84, 92 and 100 weeks


Other interventions: rituximab


Other interventions: No treatment


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time until initiation of therapy (chemotherapy or radiotherapy)</outcome>
      <timepoint>Time from randomisation until the first day systemic chemotherapy or radiotherapy is given. If rituximab is given to patients in the watch and wait arm this will be considered as initiation of chemotherapy.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Frequency of clinical spontaneous remission</outcome>
      <timepoint>From randomisation until the initiation of chemotherapy in the watch and wait arm</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Cause specific survival</outcome>
      <timepoint>Time from randomisation to death from lymphoma or immediate therapy related toxicity</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>Time from randomisation to death from any cause.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Response rate at 25 months</outcome>
      <timepoint>Response at 25 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS:

          -  Histologically confirmed follicular non-Hodgkin's lymphoma

               -  Diagnosed within the past 3 months

               -  Grade 1, 2, or 3a disease

               -  Stage II-IV disease

               -  No evidence of histological transformation

          -  Bidimensionally measurable disease by clinical examination or radiography

          -  Asymptomatic disease without B symptoms or severe pruritus

          -  Low tumor burden, defined by all of the following criteria:

               -  Lactic dehydrogenase normal

               -  Largest nodal or extranodal mass &lt; 7 cm

               -  No more than 3 nodal sites with a diameter &gt; 3 cm

               -  No clinically detectable significant serous effusion by chest x-ray

                    -  Clinically non-evident small effusion on CT scan is not considered
                       significant

               -  Spleen enlargement = 16 cm by CT scan

          -  Circulating tumor cells &lt; 5,000/mm^3

          -  No organ compression (i.e., ureteric obstruction)

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count &gt; 1,500/mm^3

          -  Platelet count &gt; 100,000/mm^3

          -  Hemoglobin &gt; 10 g/dL

        Hepatic

          -  AST and ALT normal

          -  Alkaline phosphatase normal

          -  Bilirubin normal

        Renal

          -  Creatinine &lt; 2 times upper limit of normal (unless due to lymphoma)

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception during and for 12 months after
             completion of rituximab

          -  No known HIV positivity

          -  No other malignancy within the past 2 years except curatively treated basal cell or
             squamous cell skin cancer or carcinoma in situ of the cervix

          -  No critical organ failure

          -  No other immediate life-threatening disease

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  Not specified

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  Not specified

        Other

          -  No prior therapy for lymphoma</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>120</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>600</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2022</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Queen Elizabeth Hospital - Adelaide</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Ashford Cancer Centre - Black Forest</hospital>
    <hospital>Boxhill Hospital - Box Hill</hospital>
    <hospital>Royal Brisbane and Women's Hospital - Brisbane</hospital>
    <hospital>Canberra Hospital - Canberra</hospital>
    <hospital>Concord Repatriation General Hospital - Concord</hospital>
    <hospital>Frankston Hospital - Frankston</hospital>
    <hospital>Fremantle Hospital - Fremantle</hospital>
    <hospital>Gosford Hospital - Gosford</hospital>
    <hospital>Royal Hobart Hospital - Hobart</hospital>
    <hospital>Nepean Hospital - Kingswood</hospital>
    <hospital>Lismore Base Hospital - Lismore</hospital>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <hospital>Austin Health - Melbourne</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <hospital>St Vincent's Hospital - Melbourne</hospital>
    <hospital>Mater Misericordiae Hospital - Newcastle</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <hospital>St Vincent's Hospital - Sydney</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Murray Valley Private Hospital - Wodonga</hospital>
    <hospital>Wollongong Hospital - Wollongong</hospital>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Black Forest</postcode>
    <postcode> - Box Hill</postcode>
    <postcode> - Brisbane</postcode>
    <postcode> - Canberra</postcode>
    <postcode> - Concord</postcode>
    <postcode> - Frankston</postcode>
    <postcode> - Fremantle</postcode>
    <postcode> - Gosford</postcode>
    <postcode> - Hobart</postcode>
    <postcode> - Kingswood</postcode>
    <postcode> - Lismore</postcode>
    <postcode> - Liverpool</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Newcastle</postcode>
    <postcode> - Perth</postcode>
    <postcode> - St Leonards</postcode>
    <postcode> - Sydney</postcode>
    <postcode> - Westmead</postcode>
    <postcode> - Wodonga</postcode>
    <postcode> - Wollongong</postcode>
    <postcode> - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Westlake</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Scotland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Wales</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University College, London</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Research UK</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Roche Pharma AG</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and
      help kill them or carry cancer-killing substances to them. It is not yet known whether
      rituximab is more effective than observation in treating non-Hodgkin's lymphoma.

      PURPOSE: This randomized phase III trial is studying rituximab to see how well it works
      compared to observation in treating patients with newly diagnosed stage II, stage III, or
      stage IV follicular non-Hodgkin's lymphoma with no symptoms.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00112931</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kirit Ardeshna</name>
      <address>Mount Vernon Cancer Centre at Mount Vernon Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>